Skip to main content

Table 2 MEST-C score distribution in STOP-IgAN patients

From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

  All (SUP + IMM) Supportive Care (SUP) Supportive Care plus Immunosuppression (IMM)
(N = 70) (N = 32) (N = 38)
Mesangial hypercellularity
 M0 52 (74%) 24 (75%) 28 (74%)
 M1 18 (26%) 8 (25%) 10 (26%)
Endocapillary hypercellularity
 E0 58 (83%) 27 (84%) 31 (82%)
 E1 12 (17%) 5 (16%) 7 (18%)
Segmental glomeruloscerlosis
 S0 6 (9%) 3 (9%) 3 (8%)
 S1 64 (91%) 29 (91%) 35 (92%)
Tubular atrophy/Interstitial fibrosis
 T0 41 (59%) 15 (47%) 26 (68%)
 T1 26 (37%) 17 (53%) 9 (24%)
 T2 3 (4%) 0 (0%) 3 (8%)
Crescents
 C0 48 (69%) 24 (75%) 24 (63%)
 C1 17 (24%) 7 (22%) 10 (26%)
 C2 5 (7%) 1 (3%) 4 (11%)